Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1150 ARTÍCULOS , VIENDO DEL 376 AL 390

Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease

Sagare AP, Bell RD, Zlokovic BV.

Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a011452. doi: 10.1101/cshperspect.a011452.

Association analysis of dopaminergic gene variants (Comt, Drd4 And Dat1) with Alzheimer s disease

Lin WY, Wu BT, Lee CC, Sheu JJ, Liu SH, Wang WF, Tsai CH, Liu HP, Tsai FJ.

J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):401-10.

"Untangling" the relationship between Alzheimer disease and dementia with Lewy bodies

Swerdlow RH, Newell KL.

Neurology. 2012 Nov 6;79(19):1938-9. doi: 10.1212/WNL.0b013e3182735ecf. Epub 2012 Oct 3.

Decreased expression of CCL3 in monocytes and CCR5 in lymphocytes from frontotemporal dementia as compared with Alzheimer's disease patients

Torres KC, Santos RR, de Lima GS, Ferreira RO, Mapa FC, Pereira PA, Rezende VB, Martins LC, Bicalho MA, Moraes EN, Reis HJ, Teixeira AL, Romano-Silva MA.

J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):E11-2. doi: 10.1176/appi.neuropsych.11060143.

Current status of vaccination therapies in Alzheimer's disease

Karran E.

J Neurochem. 2012 Dec;123(5):647-51. doi: 10.1111/jnc.12009. Epub 2012 Oct 11.

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients

Han HJ, Kim BC, Lee JY, Ryu SH, Na HR, Yoon SJ, Park HY, Shin JH, Cho SJ, Yi HA, Choi MS, Heo JH, Park KW, Kim KK, Choi SH.

Dement Geriatr Cogn Disord. 2012;34(3-4):167-73. doi: 10.1159/000342927. Epub 2012 Oct 5.

Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer's disease

Uwano C, Suzuki M, Aikawa T, Ebihara T, Une K, Tomita N, Kosaka Y, Okinaga S, Furukawa K, Arai H, Ohrui T.

J Am Geriatr Soc. 2012 Oct;60(10):1979-80. doi: 10.1111/j.1532-5415.2012.04182.x.

My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease

Le Bouc R, Lenfant P, Delbeuck X, Ravasi L, Lebert F, Semah F, Pasquier F.

Brain. 2012 Oct;135(Pt 10):3026-38. doi: 10.1093/brain/aws237.

Alzheimer disease: what new evidence shows

Uriri-Glover J, McCarthy M, Cesarotti E.

Nurs Manage. 2012 Nov;43(11):26-31; quiz 31-2. doi: 10.1097/01.NUMA.0000421671.10723.ad.

Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease

Abeti R, Duchen MR.

Neurochem Res. 2012 Nov;37(11):2589-96. doi: 10.1007/s11064-012-0895-x. Epub 2012 Oct 18.

Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress

Castellani RJ, Perry G.

Arch Med Res. 2012 Nov;43(8):694-8. doi: 10.1016/j.arcmed.2012.09.009. Epub 2012 Oct 16.

Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation

Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kłoszewska I, Tsolaki M, Vellas B, Spenger C, Mecocci P, Wahlund LO, Simmons A, Barnes J, Lovestone S.

J Transl Med. 2012 Oct 31;10:217. doi: 10.1186/1479-5876-10-217.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias